Mozart Therapeutics Presents Clinical and Preclinical Data Supporting MTX-101 at the 62nd EASD Annual Meeting

Barchart · 2d ago

Presentations highlight Phase 1 clinical findings, proof-of-mechanism data, and translational evidence supporting the therapeutic potential of MTX-101 in adults and adolescents with Stage 3 type 1 diabetes

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.